HongKong:01061

Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%

Retrieved on: 
星期三, 八月 16, 2023

HONG KONG, Aug 16, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").

Key Points: 
  • HONG KONG, Aug 16, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").
  • The profit of the Group increased by 22.0% to approximately HK$170 million as compared to approximately HK$139.2 million for the same period last year.
  • As of 30 June 2023, the Group had cash and cash equivalents of approximately HK$506 million (31 December 2022: approximately HK$543 million).
  • The Group's revenue is primarily made up of the segments of Ophthalmology and Surgical (wound care and healing).

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

Retrieved on: 
星期三, 七月 26, 2023

This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).

Key Points: 
  • This single-arm, open-label, multicentre, phase I/II study aimed to evaluate the safety and preliminary efficacy of EB12-20145P (HLX04-O) via intravitreal injection (IVT) in patients with active wet age-related macular degeneration (wAMD).
  • Part 2 was a single-arm, open-label, multicentre, phase II study and 20 patients (including 6 patients from part 1) were enrolled in this part.
  • As of now, the clinical trial applications of EB12-20145P (HLX04-O) had been approved in Singapore and other countries and regions.
  • EB12-20145P (HLX04-O) has the potential to be one of the first bevacizumab approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.

Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore

Retrieved on: 
星期五, 四月 14, 2023

Ltd. ("Majeton"), has entered into an exclusive Distribution Agreement with Osteopore Limited ("Osteopore") to promote and sell Osteopore's dental and oral maxillofacial products ("Products") in Singapore.

Key Points: 
  • Ltd. ("Majeton"), has entered into an exclusive Distribution Agreement with Osteopore Limited ("Osteopore") to promote and sell Osteopore's dental and oral maxillofacial products ("Products") in Singapore.
  • Pursuant to the Distribution Agreement, Majeton will be the exclusive distributor of the Products for an initial period of 3 years, starting from 2023 to 2026.
  • Osteopore's innovative oral maxilla facial products are used in guided bone regeneration, immediate implant loading, and socket preservation.
  • In unique situations, Osteopore may also make available customised regenerative implants for various oral maxillofacial reconstruction.